The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (28.51) USD. With the latest stock price at 1.38 USD, the upside of Nektar Therapeutics based on DCF is -2166.2%.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
WACC / Discount Rate | 7.2% - 10.3% | 8.8% |
Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
Fair Price | (58.58) - (19.31) | (28.51) |
Upside | -4345.3% - -1499.5% | -2166.2% |